Anuh Pharma Ltd(ANUHPHR)

NSE: ANUHPHRBSE: 506260

₹ 77.84+1.22%refreshed 26 Oct, 01:10 pm ISTMarket cap: ₹ 780 crWebsite: www.anuhpharma.comUpdated: 24 Oct 2026

About

Anuh Pharma makes active pharmaceutical ingredients (APIs), mainly macrolides such as erythromycin, anti-malarials like sulphadoxine, and anti-diabetics like gliclazide. It sells them at home and abroad. Its installed capacity is 2,400 MTPA, and it reported revenue of Rs 771.66 Cr for FY26. Its plant passed a USFDA inspection in 2026 with zero 483 observations and holds EU GMP clearances.^[1][2][3]

Product mix

Erythromycin revenue was Rs49.1 cr in Q1 FY27 vs Rs63.6 cr in Q1 FY26.^[1]
Higher macrolides revenue was Rs39.9 cr in Q1 FY27 vs Rs19.7 cr in Q1 FY26.^[1]
Sulphadoxine revenue was Rs37.0 cr in Q1 FY27 vs Rs11.0 cr in Q1 FY26.^[1]
Gliclazide revenue was Rs11.9 cr in Q1 FY27 vs Rs5.1 cr in Q1 FY26.^[1]
Amodiaquine HCL received WHO pre-qualification in 2026.^[1]
Sulfadimethoxine received a new CEP approval in 2025.^[2]

Manufacturing capacity

Installed capacity was raised from 2200 MTPA to 2400 MTPA in 2025, after an increase from 1800 to 2200 MTPA in 2024.^[4]
As of H1 FY26 the site had 2 intermediate blocks and 9 API blocks, with total reactor capacity of 240 KL, after a new intermediate block was added.^[5]
Effluent treatment capacity was expanded to 150 KL/day in H1 FY26, and solar power was added.^[5]
Solar power and waste-steam recovery have lowered power and fuel costs (Q3 FY26).^[2]
The company still depends on intermediates mainly from China and plans backward integration (FY25).^[6]

Key operating numbers

Production was 491 MT in Q1 FY27 vs 411 MT in Q1 FY26, up 19.46% YoY.^[1]
ROCE was 19.18% in Q1 FY27 vs 15.92% for FY26.^[1]

Regulatory status

The USFDA inspection in Feb-2026 closed with zero 483 observations.^[2][1]
EU GMP clearances are in place, and management calls the regulated-market pipeline its primary growth engine (Q1 FY27).^[1]

Customers and markets

The company lists 360 customers in over 59 countries (Q1 FY26).^[4]
Exports were about 46% of revenue in FY26, compared with about 55% in FY25.^[1][5]
Domestic revenue was ~Rs124 cr in Q1 FY27 vs ~Rs98 cr in Q1 FY26. Export revenue was ~Rs70 cr vs ~Rs88 cr.^[1]
Domestic sales were ₹307 Cr in 9M FY26 vs ₹220 Cr in 9M FY25. Exports were ₹260 Cr vs ₹241 Cr.^[2]
Asia's share of exports was 44% in H1 FY26, up from 30%.^[5]
Problems with US dollar remittances in Africa affect exports (FY25).^[6]

Pipeline and growth plans

Products under development as of Q1 FY27 include Vonoprazan Fumarate, Pretomanid, Edoxaban Tosylate and Bisoprolol Fumarate.^[1]
In Q3 FY26 the pipeline had 9 products under development, including Linagliptin, Empagliflozin, Pretomanid and Bedaquiline.^[2]
The pipeline covers diabetic care, anticoagulants and next-generation anti-malarials, and the company is advancing select CDMO opportunities (H1 FY26).^[5]
Management expects revenue growth of 15-20% per annum (stated Q1 FY27).^[1]
The company plans briquette-fired boilers to reduce exposure to crude oil prices (FY25).^[6]

Recent developments

A dedicated CMO was appointed to drive growth in regulated markets (H1 FY26).^[5]
The pay of both Joint Managing Directors was revised from 1 April 2026.^[7]
The company is adopting a new Memorandum and Articles of Association to align with the Companies Act 2013 (FY26 annual report).^[7]

Market Cap

₹780 Cr

High / Low

₹100 / 67

Stock P/E

17.2

Price / Book

2.2

Book Value

₹35

EPS

₹4.1

No. of Shares

10.02 Cr

ROCE

15.9%

ROE

12.1%

OPM

7.0%

Debt / Equity

0.00

Sales

₹772 Cr

Net Profit

₹41 Cr

Promoter holding

71.8%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials